CN110840939A - 一种根治心脑血栓的药物及其制备方法 - Google Patents
一种根治心脑血栓的药物及其制备方法 Download PDFInfo
- Publication number
- CN110840939A CN110840939A CN201810817411.8A CN201810817411A CN110840939A CN 110840939 A CN110840939 A CN 110840939A CN 201810817411 A CN201810817411 A CN 201810817411A CN 110840939 A CN110840939 A CN 110840939A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- preparation
- heart
- pulverizing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 201000001429 Intracranial Thrombosis Diseases 0.000 title claims abstract description 15
- 229940079593 drug Drugs 0.000 title claims description 3
- 230000000747 cardiac effect Effects 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 238000010298 pulverizing process Methods 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 241000545744 Hirudinea Species 0.000 claims abstract description 8
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 7
- 241000237903 Hirudo Species 0.000 claims abstract description 6
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 4
- 241000402754 Erythranthe moschata Species 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 244000153234 Hibiscus abelmoschus Species 0.000 claims abstract description 4
- 241000243684 Lumbricus Species 0.000 claims abstract description 4
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 4
- 241000219061 Rheum Species 0.000 claims abstract description 4
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims abstract description 4
- 241000522620 Scorpio Species 0.000 claims abstract description 4
- 241000239226 Scorpiones Species 0.000 claims abstract description 4
- 229940116229 borneol Drugs 0.000 claims abstract description 4
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims abstract description 4
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000007721 medicinal effect Effects 0.000 claims abstract description 4
- 238000000643 oven drying Methods 0.000 claims abstract description 4
- 238000012545 processing Methods 0.000 claims abstract description 4
- 239000009490 scorpio Substances 0.000 claims abstract description 4
- 238000002791 soaking Methods 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 4
- 206010008132 Cerebral thrombosis Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 206010061216 Infarction Diseases 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000006 Nitroglycerin Substances 0.000 claims description 2
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 2
- 241000180649 Panax notoginseng Species 0.000 claims description 2
- 206010033799 Paralysis Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 238000009098 adjuvant therapy Methods 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- -1 decoction Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 claims description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000007574 infarction Effects 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 108010056764 Eptifibatide Proteins 0.000 abstract description 3
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 abstract description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 3
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 abstract description 3
- 229960004468 eptifibatide Drugs 0.000 abstract description 3
- 231100000252 nontoxic Toxicity 0.000 abstract description 3
- 230000003000 nontoxic effect Effects 0.000 abstract description 3
- 229960005356 urokinase Drugs 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 208000007536 Thrombosis Diseases 0.000 description 5
- 108090000190 Thrombin Proteins 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Insects & Arthropods (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
一种根治心脑血栓的药物及其制备方法，它涉及中药技术领域，具体涉及一种根治心脑血栓的药物及其制备方法，它的原料按其重量占原料总重量的份数配比如下：水蛭10份、地龙10份、大黄2份、全虫6份、麝香0.03份，冰片1份；它的制备方法如下：水蛭用传统滑石粉炮制后粉碎，地龙用黄酒浸泡两小时后，然后烘干粉碎，去其腥臭保留药性，大黄、全虫物理粉碎，麝香、冰片作为增效剂用95％的酒精雾化加入。采用上述技术方案后，本发明有益效果为：它不仅安全无毒无副作用，廉价高效，可与尿激酶和依替巴肽比较功效相当，而且方便携带服用，用量调整幅度大。
Description
技术领域
本发明涉及中药技术领域，具体涉及一种根治心脑血栓的药物及其制备方法。
背景技术
水蛭是一种世界性的药物，重要主要炮制品内服已有2000年的历史。1990年山东医药工业报道，用(水蛭提取物)脑心康口服液治疗高血压、脑血管出血180例，每次100ML，每日3次，4至6周为一个疗程，结果痊愈107例，有效率达90％。
但是，现有活血抗凝的方法，仅停留在对单味中药的实验与临床应用上，据浙江中医杂志1991、广州医学院学报1986中西医结合杂志1988等均有报道，其疗程长，疗效不显著。
发明内容
本发明的目的在于针对现有技术的缺陷和不足，提供一种根治心脑血栓的药物及其制备方法，它不仅安全无毒无副作用，廉价高效，可与尿激酶和依替巴肽比较功效相当，而且方便携带服用，用量调整幅度大。
为实现上述目的，本发明采用以下技术方案是：它的原料按其重量占原料总重量的份数配比如下：水蛭10份、地龙10份、大黄2份、全虫6份、麝香0.03份，冰片1份；
它的制备方法如下：水蛭用传统滑石粉炮制后粉碎，地龙用黄酒浸泡两小时后，然后烘干粉碎，去其腥臭保留药性，大黄、全虫物理粉碎，麝香、冰片作为增效剂用95％的酒精雾化加入。
所述药物的剂型为冲剂、汤剂、片剂、胶囊或注射剂的其中一种。
它具有以下作用：a、抗血凝作用，显著延长蛋白原的凝聚时间。药物中的有效成份能与凝血酶结合，形成一种共价复合物而且反应速度极快，其中主要药物水蛭与凝血酶的亲和力极强，在低浓度下就能中和凝血酶，使凝血酶与血小板解离，从而产生的抗凝血作用；b、抗血栓作用，根据现代中药研究与临床使用报道，水蛭的复方合剂，对纤维蛋白产生的纤溶解作用，适量的水蛭素能明显抑制人体的血栓形成，以及血管壁损伤形成的颈动脉血栓和冠状动脉血栓的形成，与肝素比较，具有不增加消耗抗凝血酶的特点。
采用上述技术方案后，本发明有益效果为：它不仅安全无毒无副作用，廉价高效，可与尿激酶和依替巴肽比较功效相当，而且方便携带服用，用量调整幅度大。
具体实施方式
实施例1：
本具体实施方式采用的技术方案是：用于治疗急性卒中，它的原料按其重量占原料总重量的份数配比如下：水蛭10份、地龙10份、大黄2份、全虫6份、麝香0.03份，冰片1份；
它的制备方法如下：水蛭用传统滑石粉炮制后粉碎，水蛭粉中加入冰片，地龙用黄酒浸泡两小时后，然后烘干粉碎，去其腥臭保留药性，大黄、全虫物理粉碎，麝香、冰片作为增效剂用95％的酒精雾化加入。
实施例2：
本实施例与实施例1的不同之处在于：用于治疗脑血栓后遗症，肢体偏瘫痪且血压偏高者另加天麻、葛根粉。
其他原料和制备方法均和实施例1相同。
实施例3：本实施例与实施例1的不同之处在于：用于治疗心脏梗死，依病情加硝酸甘油。
其他原料和制备方法均和实施例1相同。
实施例4：本实施例与实施例1的不同之处在于：用于治疗急性脑出血，原料中另加三七，且依病情加甘露醇，或采用现代科技药物辅助治疗。
其他原料和制备方法均和实施例1相同。
它通过对传统中药的临床反复试验，确立新型配伍。在制作工艺上，以逐味中药按国家药典要求，采取烘烤粉碎，增效药物雾化加入的方法，使之达到协同增效的目的。
以上所述，仅用以说明本发明的技术方案而非限制，本领域普通技术人员对本发明的技术方案所做的其它修改或者等同替换，只要不脱离本发明技术方案的精神和范围，均应涵盖在本发明的权利要求范围当中。
Claims (7)
1.一种根治心脑血栓的药物，其特征在于：它的原料按其重量占原料总重量的份数配比如下：水蛭10份、地龙10份、大黄2份、全虫6份、麝香0.03份，冰片1份。
2.一种根治心脑血栓的药物制备方法，其特征在于：它的制备方法如下：水蛭用传统滑石粉炮制后粉碎，地龙用黄酒浸泡两小时后，然后烘干粉碎，去其腥臭保留药性，大黄、全虫物理粉碎，麝香、冰片作为增效剂用95％的酒精雾化加入。
3.根据权利要求1所述的一种根治心脑血栓的药物，其特征在于：所述药物的剂型为冲剂、汤剂、片剂、胶囊或注射剂的其中一种。
4.根据权利要求1所述的一种根治心脑血栓的药物制备方法，其特征在于：用于治疗急性卒中，水蛭粉中另加冰片。
5.根据权利要求1所述的一种根治心脑血栓的药物制备方法，其特征在于：用于治疗脑血栓后遗症，肢体偏瘫痪且血压偏高者另加天麻、葛根粉。
6.根据权利要求1所述的一种根治心脑血栓的药物及其制备方法，其特征在于：用于治疗心脏梗死，依病情加硝酸甘油。
7.根据权利要求1所述的一种根治心脑血栓的药物制备方法，其特征在于：用于治疗急性脑出血，原料中另加三七，且依病情加甘露醇，或采用现代科技药物辅助治疗。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810817411.8A CN110840939A (zh) | 2018-07-24 | 2018-07-24 | 一种根治心脑血栓的药物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810817411.8A CN110840939A (zh) | 2018-07-24 | 2018-07-24 | 一种根治心脑血栓的药物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110840939A true CN110840939A (zh) | 2020-02-28 |
Family
ID=69594212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810817411.8A Pending CN110840939A (zh) | 2018-07-24 | 2018-07-24 | 一种根治心脑血栓的药物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110840939A (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1085442A (zh) * | 1993-07-27 | 1994-04-20 | 李嘉宾 | 一种预防、治疗脑中风的药物 |
| CN1281709A (zh) * | 2000-07-06 | 2001-01-31 | 盛华海 | 一种治疗血栓病的中成药 |
| CN101085229A (zh) * | 2006-06-05 | 2007-12-12 | 李凤池 | 治疗脑血栓的药物 |
| CN107296898A (zh) * | 2017-04-13 | 2017-10-27 | 钓鱼台医药集团吉林天强制药股份有限公司 | 麝香抗栓丸及其制备方法 |
-
2018
- 2018-07-24 CN CN201810817411.8A patent/CN110840939A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1085442A (zh) * | 1993-07-27 | 1994-04-20 | 李嘉宾 | 一种预防、治疗脑中风的药物 |
| CN1281709A (zh) * | 2000-07-06 | 2001-01-31 | 盛华海 | 一种治疗血栓病的中成药 |
| CN101085229A (zh) * | 2006-06-05 | 2007-12-12 | 李凤池 | 治疗脑血栓的药物 |
| CN107296898A (zh) * | 2017-04-13 | 2017-10-27 | 钓鱼台医药集团吉林天强制药股份有限公司 | 麝香抗栓丸及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 孙灌宁等: "蛭龙通栓胶囊的制备及质量标准研究 ", 《社区医学杂志》 * |
| 王鹂等: "解毒通络法对血栓形成大鼠AT-Ⅲ活性及D-二聚体含量的影响 ", 《中西医结合心脑血管病杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101919927B (zh) | 一种治疗烫伤的喷雾剂 | |
| CN110840939A (zh) | 一种根治心脑血栓的药物及其制备方法 | |
| CN105963527A (zh) | 伤口快速愈合中药提取液及其制备方法 | |
| CN102178697B (zh) | 一种复方水蛭胶囊及其制备方法 | |
| CN101559125B (zh) | 烧伤散 | |
| CN102920800B (zh) | 一种外用药物组合物及其应用和制备方法 | |
| CN105663404A (zh) | 一种治疗子宫内膜炎的药物 | |
| CN101036712A (zh) | 烫烧伤软膏 | |
| CN106421410A (zh) | 一种治疗糖尿病足的中药组合物 | |
| CN106421010A (zh) | 一种肃水圣草烧伤液及其制备方法 | |
| CN110856734A (zh) | 一种预防创面感染的中药组合物及其制备方法 | |
| CN107158311B (zh) | 治疗人体深度烧灼伤的纯中药制剂 | |
| CN104116935A (zh) | 一种治疗脑血栓的中药 | |
| CN104147366A (zh) | 治疗烧烫伤、疮痈外用药膏及制备方法 | |
| CN105168331B (zh) | 一种预防和治疗鸡球虫病的复方中药及其制备方法 | |
| CN103463524B (zh) | 一种治疗骨髓炎的中药组合物及其制备方法 | |
| CN104547929B (zh) | 一种治疗中风后遗症的中药及制备方法 | |
| CN104524017A (zh) | 一种治疗脉管炎的中药制剂 | |
| CN103735724A (zh) | 治疗冠心病的中药 | |
| CN103099853B (zh) | 肾康注射液在制备防治深静脉栓塞药物中的应用 | |
| CN108524710A (zh) | 一种治疗关节疼痛的中药组合物及其制备方法和应用 | |
| CN109893605A (zh) | 一种外用治疗静脉炎的中草药药液 | |
| CN112353937A (zh) | 仙鹤草鲜药冻干粉复合制剂 | |
| CN111759882A (zh) | 一种治疗椎间盘突出的纯中药透皮擦剂及其制备方法 | |
| CN101757218A (zh) | 用于治疗烧伤的外用药及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200228 |